An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia

the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and Participating Survey Investigators

doi:10.1111/hae.13238

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia

the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and Participating Survey Investigators

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English
Pages (from-to)	e447-e450
Journal	Haemophilia
Volume	23
Issue number	5
DOIs	https://doi.org/10.1111/hae.13238
State	Published - Sep 2017

Access to Document

10.1111/hae.13238

Cite this

@article{11751b7a3f5541bca55cb2619831c8f1,

title = "An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia",

author = "\{the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and Participating Survey Investigators\} and Carcao, \{M. D.\} and L. Avila and C. Leissinger and Blanchette, \{V. S.\} and L. Aledort",

note = "Funding Information: We thank all those who contributed data for this survey as well as the staff members at the coordinating center (Audrey Abad, Dan Ignas and Nicole Rivera) and the funders of the International Prophylaxis Study Group (IPSG): Baxalta (now a part of Shire); Bayer Healthcare; Biogen Idec; CSL Behring; Pfizer and Novo Nordisk Healthcare AG. The funding for the IPSG is provided through grants administered by The Hospital for Sick Children Foundation, Toronto, Canada.",

year = "2017",

month = sep,

doi = "10.1111/hae.13238",

language = "English",

volume = "23",

pages = "e447--e450",

journal = "Haemophilia",

issn = "1351-8216",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

TY - JOUR

T1 - An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia

AU - the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and Participating Survey Investigators

AU - Carcao, M. D.

AU - Avila, L.

AU - Leissinger, C.

AU - Blanchette, V. S.

AU - Aledort, L.

N1 - Funding Information: We thank all those who contributed data for this survey as well as the staff members at the coordinating center (Audrey Abad, Dan Ignas and Nicole Rivera) and the funders of the International Prophylaxis Study Group (IPSG): Baxalta (now a part of Shire); Bayer Healthcare; Biogen Idec; CSL Behring; Pfizer and Novo Nordisk Healthcare AG. The funding for the IPSG is provided through grants administered by The Hospital for Sick Children Foundation, Toronto, Canada.

PY - 2017/9

Y1 - 2017/9

UR - https://www.scopus.com/pages/publications/85018635443

U2 - 10.1111/hae.13238

DO - 10.1111/hae.13238

M3 - Letter

C2 - 28429874

AN - SCOPUS:85018635443

SN - 1351-8216

VL - 23

SP - e447-e450

JO - Haemophilia

JF - Haemophilia

IS - 5

ER -